<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853719</url>
  </required_header>
  <id_info>
    <org_study_id>ScienceValley</org_study_id>
    <nct_id>NCT04853719</nct_id>
  </id_info>
  <brief_title>Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients</brief_title>
  <official_title>A Prospective, Randomized, Open-label, Multicenter Study Comparing Rivaroxaban 2.5 mg Twice Daily Associated With Aspirin 100 mg Once Daily Versus Aspirin 100 mg Once Daily in Patients With Peripheral Arterial Disease and Limiting Intermittent Claudication. (The COMPASS CLAUDICATION Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Science Valley Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Science Valley Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is evaluating if rivaroxaban 2.5 mg BID and aspirin 100 mg OD compared to aspirin&#xD;
      alone improves on intermittent claudication distance in PAD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The COMPASS trial demonstrated that in patients with peripheral arterial disease&#xD;
      the combination of rivaroxaban and aspirin compared with aspirin reduces the risk of major&#xD;
      adverse limb events, but it is not known whether this combination can also improve symptoms&#xD;
      in patients with intermittent claudication. The primary objective of this study is to&#xD;
      evaluate the effect of the combination on intermittent claudication distance.&#xD;
&#xD;
      Study design: Eighty-eight patients with intermittent claudication will be randomized to&#xD;
      receive rivaroxaban 2,5 mg twice daily plus aspirin 100 mg once daily or aspirin 100 mg once&#xD;
      daily for 24 weeks. The primary outcome is the change in claudication distance from baseline&#xD;
      to 24 hours as measured by 6 minutes walking test and treadmill test. The main safety outcome&#xD;
      is the incidence of major bleeding according to ISTH criteria.&#xD;
&#xD;
      Summary: The COMPASS CLAUDICATION trial will provide high-quality evidence regarding the&#xD;
      effect of the combination of rivaroxaban and aspirin on claudication distance in patients&#xD;
      with peripheral arterial disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 arms, active comparator (vascular dose) versus aspirin alone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Initial claudication distance (ICD) and the total walking distance (TWD) on 6 MWT</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement of the initial claudication distance (ICD) and the total walking distance (TWD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute claudication distance (ACD) on treadmill</measure>
    <time_frame>6 months</time_frame>
    <description>ACD is the total distance traveled on a treadmill until it stops due to IC pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life Walking Impairment Questionnaire (WIQ):</measure>
    <time_frame>6 months</time_frame>
    <description>A modified version of WiQ will be administered at baseline and 12 and 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular event</measure>
    <time_frame>6 months</time_frame>
    <description>Exploratory: major adverse cardiovascular events - MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events of the limbs</measure>
    <time_frame>6 months</time_frame>
    <description>MALE - acute limb ischemia</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Exploratory outcomes (major bleeding + clinically non-relevant bleeding) will be used, according to the International Society's bleeding criteria on Thrombosis and Hemostasis (ISTH).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>Vascular dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 100 mg OD for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 Mg Oral Tablet</intervention_name>
    <description>oral anticoagulants plus antiplatelet agent</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Vascular dose</arm_group_label>
    <other_name>Aspirin 100 Mg oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic PAD who signed the informed consent form (ICF) with:&#xD;
&#xD;
               1. Ankle-brachial index (ABI) &lt; 0. 85 in at least one member, and&#xD;
&#xD;
               2. ACD &lt; 500 meters&#xD;
&#xD;
               3. age &gt; 18 years&#xD;
&#xD;
               4. No history of lower-limbs arterial bypass surgery or angioplasties in the last&#xD;
                  year&#xD;
&#xD;
               5. walking ability limited by the symptom of claudication and&#xD;
&#xD;
               6. ability to complete a treadmill test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. high risk of bleeding&#xD;
&#xD;
             - Evidence of a recent history of bleeding in the last three months, hemorrhagic&#xD;
             diathesis in the last three months, changes in coagulation tests (INR&gt; 1.5 or aPTT &gt;&#xD;
             2), pulmonary bronchiectasis, active cancer, active gastroduodenal ulcer, use of dual&#xD;
             antiplatelet therapy.&#xD;
&#xD;
          2. Recent hemorrhagic stroke (1 month) or any history of previous hemorrhagic or lacunar&#xD;
             stroke, if detected by occasional prior tomography, which is not part of the study&#xD;
             protocol.&#xD;
&#xD;
          3. severe heart failure (NYHA class III and VI)&#xD;
&#xD;
          4. advanced stable kidney disease (estimated creatinine clearance &lt;15 ml per minute),&#xD;
             defined as eTFG &lt;15 mL/min by 1.73 m2 calculated by the abbreviated formula Diet&#xD;
             Modification in Kidney Disease (MDRD).&#xD;
&#xD;
          5. the use of dual antiplatelet therapy, anticoagulation, or other antithrombotic therapy&#xD;
&#xD;
          6. Continuous use of pentoxifylline or cilostazol&#xD;
&#xD;
          7. Cardiac conditions that may lead to heart failure, such as unstable angina,&#xD;
             arrhythmias, acute myocardial infarction in the last three months&#xD;
&#xD;
          8. Non-cardiac conditions that may interfere with the ability to complete functional&#xD;
             tests (e.g., chronic obstructive pulmonary disease, anemia, rheumatologic diseases)&#xD;
&#xD;
          9. Non-cardiovascular conditions are considered by the researcher as associated with a&#xD;
             poor prognosis.&#xD;
&#xD;
        a. Active cancer with a life expectancy of fewer than six months b. Collagen limiting&#xD;
        diseases c. Previous or scheduled surgeries that prevent functional evaluation d.&#xD;
        Orthopedic diseases that hinder functional evaluation (j) Pregnancy. Women with the&#xD;
        potential to bear children should be under contraceptive strategies and take a negative&#xD;
        pregnancy test to be enrolled.&#xD;
&#xD;
        (k) Patients with COVID in the contagious phase (PCR+)&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Science Valley Research Institute</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09030370</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Agati, PhD</last_name>
      <phone>+551144688183</phone>
      <email>agati@svriglobal.com</email>
    </contact>
    <contact_backup>
      <last_name>Eduardo Ramacciotti, MD, PhD</last_name>
      <phone>+551144688183</phone>
      <email>ramacciotti@svriglobal.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IAMSPE - Sao Paulo Public Servants Hospital</name>
      <address>
        <city>São Paulo</city>
        <zip>04039000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo B Biagioni</last_name>
      <phone>11981871545</phone>
      <email>rbbiagioni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Sacilotto, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data is collected on RedCap, thast allows open and sharing IPD</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

